Coverage
-
August 06, 2012
A federal jury in Massachusetts found Friday that drugmakers Seikagaku Corp. and Zimmer Inc. hadn't infringed Genzyme Corp.'s patent for osteoarthritis knee pain treatment Synvisc-One by marketing a rival pain treatment. (A previous version of this article incorrectly described Seikagaku's product as a generic drug.)
4 other articles on this case.
View all »